Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA
OSLO, Norway, 11 June 2007 - Clavis Pharma (OSE: CLAVIS)
presented an update of data from its ongoing clinical Phase I/II
study with ELACYT
in hematologic cancers during a poster session at
the Annual Meeting of the European Hematology Association (EHA) in
is a novel cytotoxic agent...